The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer

Por James, Nicole E., Woodman, Morgan, DiSilvestro, Paul A., Ribeiro, Jennifer R.
Publicado no Cancers (Basel) (2020)

Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Fa...

Por Rose, Peter G., Java, James, Whitney, Charles W., Stehman, Frederick B., Lanciano, Rachelle, Thomas, Gillian M., DiSilvestro, Paul A.
Publicado no J Clin Oncol (2015)

Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?

Por Moore, Richard G., Blackman, Alexandra, Miller, M. Craig, Robison, Katina, DiSilvestro, Paul A., Eklund, Elizabeth E., Strongin, Robert, Messerlian, Geralyn
Publicado no Gynecol Oncol (2019)

A Phase II Evaluation of Belinostat and Carboplatin in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma: A Gynec...

Por Dizon, Don S., Blessing, John A., Penson, Richard T., Drake, Richard D., Walker, Joan L., Johnston, Carolyn M., DiSilvestro, Paul A., Fader, Amanda Nickles
Publicado em 2012

Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer via Regulation of the Extracelluar Matrix

Por Ribeiro, Jennifer R., Gaudet, Hilary M., Khan, Mehreen, Schorl, Christoph, James, Nicole E., Oliver, Matthew T., DiSilvestro, Paul A., Moore, Richard G., Yano, Naohiro
Publicado no Front Oncol (2018)

Addressing clinical trials: Can the Multidisciplinary Tumor Board improve participation? A study from an academic women's cancer program()

Por Kuroki, Lindsay, Stuckey, Ashley, Hirway, Priya, Raker, Christina A., Bandera, Christina A., DiSilvestro, Paul A., Granai, Cornelius O., Legare, Robert D., Sakr, Bachir J., Dizon, Don S.
Publicado no Gynecol Oncol (2009)

A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untre...

Por Gould, Natalie, Sill, Michael W., Mannel, Robert S., Thaker, Premal H., DiSilvestro, Paul A., Waggoner, Steven E., Yamada, S. Diane, Armstrong, Deborah K., Fracasso, Paula M., Walker, Joan L.
Publicado no Gynecol Oncol (2012)

Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes

Por James, Nicole E., Beffa, Lindsey, Oliver, Matthew T., Borgstadt, Ashley D., Emerson, Jenna B., Chichester, Clinton O., Yano, Naohiro, Freiman, Richard N., DiSilvestro, Paul A., Ribeiro, Jennifer R.
Publicado no Oncotarget (2019)

A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, Bevacizumab and Veliparib in Recurrent, Platinum-Sensitive Ovarian, Primary Peritoneal, and Fallopian Tube Ca...

Por Landrum, Lisa M., Brady, William E., Armstrong, Deborah K., Moore, Kathleen N., DiSilvestro, Paul A., O'Malley, David M., Tenney, Meaghan E., Rose, Peter G., Fracasso, Paula M.
Publicado no Gynecol Oncol (2015)

BEVACZIUMAB PLUS FOSBRETABULIN IN RECURRENT OVARIAN CANCER: OVERALL SURVIVAL AND EXPLORATORY ANALYSES OF A RANDOMIZED PHASE II NRG ONCOLOGY/GYNECOLOGIC ONCOLOGY GROUP STUDY

Por Tewari, Krishnansu S., Sill, Michael W., Coleman, Robert L., Aghajanian, Carol, Mannel, Robert, DiSilvestro, Paul A., Powell, Matthew, Randall, Leslie M., Farley, John, Rubin, Stephen C., Monk, Bradley J.
Publicado no Gynecol Oncol (2020)

Septin-2 is overexpressed in epithelial ovarian cancer and mediates proliferation via regulation of cellular metabolic proteins

Por James, Nicole E., Cantillo, Evelyn, Yano, Naohiro, Chichester, Clinton O., DiSilvestro, Paul A., Hovanesian, Virginia, Rao, R. Shyama Prasad, Kim, Kyukwang K., Moore, Richard G., Ahsan, Nagib, Ribeiro, Jennifer R.
Publicado no Oncotarget (2019)

Phase III Randomized Trial of Weekly Cisplatin and Irradiation Versus Cisplatin and Tirapazamine and Irradiation in Stages IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited t...

Por DiSilvestro, Paul A., Ali, Shamshad, Craighead, Peter S., Lucci, Joseph A., Lee, Yi-Chun, Cohn, David E., Spirtos, Nicola M., Tewari, Krishnasu S., Muller, Carolyn, Gajewski, Walter H., Steinhoff, Margaret M., Monk, Bradley J.
Publicado em 2014

Phase II Trial of Trastuzumab in Women with Advanced or Recurrent, HER2-Positive Endometrial Carcinoma: a Gynecologic Oncology Group Study

Por Fleming, Gini F., Sill, Michael W., Darcy, Kathleen M., McMeekin, D. Scott, Thigpen, J. Tate, Adler, Lisa M., Berek, Jonathan S., Chapman, Julia A., DiSilvestro, Paul A., Horowitz, Ira R., Fiorica, James V.
Publicado em 2009

Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6

Por James, Nicole E., Oliver, Matthew T., Ribeiro, Jennifer R., Cantillo, Evelyn, Rowswell-Turner, Rachael B., Kim, Kyu-Kwang, Chichester, Clinton O., DiSilvestro, Paul A., Moore, Richard G., Singh, Rakesh K., Yano, Naohiro, Zhao, Ting C.
Publicado no Front Pharmacol (2019)

The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes

Por James, Nicole E., Emerson, Jenna B., Borgstadt, Ashley D., Beffa, Lindsey, Oliver, Matthew T., Hovanesian, Virginia, Urh, Anze, Singh, Rakesh K., Rowswell-Turner, Rachael, DiSilvestro, Paul A., Ou, Joyce, Moore, Richard G., Ribeiro, Jennifer R.
Publicado no Sci Rep (2020)

A Phase II Evaluation of Pazopanib in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study

Por Campos, Susana M., Brady, William E., Moxley, Katherine M., O'Cearbhaill, Roisin E., Lee, Paula S., DiSilvestro, Paul A., Rotmensch, Jacob, Rose, Peter G., Thaker, Premal H., O'Malley, David M., Hanjani, Parviz, Zuna, Rosemary E., Hensley, Martee L.
Publicado no Gynecol Oncol (2014)

Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice

Por Cohn, David E., Havrilesky, Laura J., Osann, Kathryn, Lipscomb, Joseph, Hsieh, Susie, Walker, Joan L., Wright, Alexi A., Alvarez, Ronald D., Karlan, Beth Y., Bristow, Robert E., DiSilvestro, Paul A., Wakabayashi, Mark T., Morgan, Robert, Mukamel, Dana B., Wenzel, Lari
Publicado no Gynecol Oncol (2015)

Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data...

Por Moore, Kathleen N., Java, James J., Slaughter, Katrina N., Rose, Peter G., Lanciano, Rachelle, DiSilvestro, Paul A., Thigpen, J. Tate, Lee, Yi-Chun, Tewari, Krishnansu S., Chino, Junzo, Seward, Shelly M., Miller, David S., Salani, Ritu, Moore, David H., Stehman, Frederick B.
Publicado no Gynecol Oncol (2016)

FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

Por Jeske, Yvette W., Ali, Shamshad, Byron, Sara A, Gao, Feng, Mannel, Robert S, Ghebre, Rahel G, DiSilvestro, Paul A, Lele, Shashikant B, Pearl, Michael L, Schmidt, Amy P, Lankes, Heather A, Ramirez, Nilsa C, Rasty, Golnar, Powell, Matthew, Goodfellow, Paul J, Pollock, Pamela M
Publicado no Gynecol Oncol (2017)

A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group st...

Por Jandial, Danielle A., Brady, William E., Howell, Stephen B., Lankes, Heather A., Schilder, Russell J., Beumer, Jan H., Christner, Susan M., Strychor, Sandra, Powell, Matthew A., Hagemann, Andrea R., Moore, Kathleen N., Walker, Joan L., DiSilvestro, Paul A., Duska, Linda R., Fracasso, Paula M., Dizon, Don S.
Publicado no Gynecol Oncol (2017)